| Literature DB >> 26491337 |
Petra Maresova1, Marek Penhaker2, Ali Selamat3, Kamil Kuca4.
Abstract
The high quality of public health improves not only healthy life expectancy, but also the productivity of labor. The most important part of the health care sector is the medical technology industry. The aim of this study is to analyze the current situation in the medical device industry in Europe, its potential strengths and weaknesses in the context of topical economic and demographic development. The contribution specifies an analysis of the economic state of the medical device industry in the context of demographic development of European Union's macroeconomic indicators and views of experts in the field of medical device development, concerning the opportunities for entities involved in the medical device market. There is fierce competition on the European market. The innovative activity is stable and well regulated by responsible authorities. Worldwide, the medical device market is expected to grow.Entities:
Keywords: Europe; expenditure; medical device; review; technology context
Year: 2015 PMID: 26491337 PMCID: PMC4599058 DOI: 10.2147/TCRM.S88574
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Figure 1Interest in the emerging markets.
Note: Data from Emergo Group.18
Figure 2European medical technology market growth rates, based upon the manufacturer process, 2008–2013.
Note: Data from Medtech Europe.1
Figure 3Aging population.
Note: Data from Eurostat.25
Total number of people in tertiary education in the EU (%)
| Year | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EU average | 22.4 | 22.8 | 23.5 | 25.0 | 26.9 | 28.0 | 28.9 | 30.0 | 31.0 | 32.2 | 33.5 | 34.6 | 35.8 |
Note: Data from Eurostat.25
Abbreviation: EU, European Union.
SWOT analysis of the EU medical device industry
| Criterion | Significance | Total impact | |
|---|---|---|---|
| High expenditures on health care, particularly on medical technologies | 5 | 0.15 | 0.75 |
| Well-developed industry with a strong manufacturing base | 3 | 0.08 | 0.24 |
| Macroeconomic and price stability of the sector | 2 | 0.05 | 0.1 |
| Quality research centers | 4 | 0.15 | 0.6 |
| Increasing annual growth of science and research expenditures | 4 | 0.12 | 0.48 |
| Existing qualified workforce | 4 | 0.2 | 0.8 |
| Existing strategic development goals | 4 | 0.1 | 0.4 |
| Existing and new business incubators and science and technology research parks | 3 | 0.1 | 0.3 |
| Growth of the medical device industry | 4 | 0.05 | 0.2 |
| Total | 1 | ||
| Disunited legislative environment in EU countries | 4 | 0.1 | 0.4 |
| Administratively demanding system of public support | 4 | 0.08 | 0.32 |
| Fragmented consultancy in the fields of public support subsidies and legislation | 3 | 0.1 | 0.3 |
| A lack of strong linkages between industries and academia | 4 | 0.18 | 0.72 |
| Insufficient coordination and standardization of the medical device industry development | 3 | 0.12 | 0.36 |
| Uncooperative research centers | 3 | 0.17 | 0.51 |
| Legislative difficulties of transferring scientific results in company practice | 4 | 0.1 | 0.4 |
| Low utilization of risk capital to financing | 2 | 0.1 | 0.2 |
| Total | 1 | ||
| Favorable demographics, namely an aging population in the developed world and a higher number of active elderly people will lead to an increase in demand for medical devices and medical services | 5 | 0.2 | 1 |
| Medical device industry is expected to grow in countries like the People’s Republic of China with their expanding middle class in emerging markets | 4 | 0.1 | 0.4 |
| Significant export potential to the developing as well as developed countries | 5 | 0.05 | 0.25 |
| Existence of clear visions, objectives and strategies for the future | 5 | 0.08 | 0.4 |
| Development of existing and new clusters in the field of the medical device industry | 2 | 0.07 | 0.14 |
| Increased accessibility of risk capital sources for financing companies’ developmental activities | 2 | 0.1 | 0.2 |
| Purpose-oriented financing of science and research | 4 | 0.1 | 0.4 |
| Coordination of scientific research institutes | 4 | 0.15 | 0.6 |
| Coordination and unification of law related to the medical device industry | 4 | 0.15 | 0.6 |
| Total | 1 | ||
| Continuing stagnation of the EU economy | 3 | 0.1 | 0.3 |
| Financial and time difficulties involved in the development of innovative medical devices | 3 | 0.08 | 0.24 |
| Underestimated significance of marketing for entering foreign markets | 4 | 0.1 | 0.4 |
| Underrated R&D cooperation in clusters | 3 | 0.1 | 0.3 |
| A lack of workplaces with efficient systems for transferring science and research results | 3 | 0.18 | 0.54 |
| Preference given to short-term development goals | 5 | 0.15 | 0.75 |
| Little use of cooperation and connections among universities, scientific research institutes and institutions supporting innovative entrepreneurship capacities | 5 | 0.17 | 0.85 |
| Total | 1 |
Notes: Criterion of each item on the scale from 1 to 5. The total impact column was created as the product of “Criteria*Significance”.
Abbreviations: EU, European Union; R&D, research and development.
SWOT analysis comparison in developed and developing countries
| USA, Israel, and UK | Mexico, Turkey, and People’s Republic of China | Authors’ study | |
|---|---|---|---|
| Strengths | Powerful brand, strong R&D capability, large numbers of patents, licensed production | Production capacity, human resources, dynamics of export, supportive legislation | Existing qualified workforce, high expenditures on health care (on medical technologies) |
| Weaknesses | Quality management deficiency, large scale of fixed investment, poor financial managing ability | Lack of innovation, lack of industrial policy, low added value | A lack of strong linkages between industries and academia, uncooperative research centers |
| Threats | Global financial crisis, strong competition, customer bargain power, regulatory environment | Competing countries, insecurity in the country, cartels | Preference given to short-term development goals, little use of cooperation, stagnation of the EU economy |
| Opportunities | Aging global population, new health care system reform, international aggregate demand, entering new markets | Human resources, increasing aggregate demand, lack of supply and market expansion | Increased accessibility of risk capital sources, existence of clear visions, coordination and unification of law related to the medical device industry |
Abbreviations: EU, European Union; R&D, research and development; SWOT, strengths, weaknesses, opportunities, and threats.
Figure 4Financing among individual entities.